All In Biotech

NDA 209606 · Bristol Myers Squibb

Idhifa

Enasidenib Mesylate · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Jan 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Aug 1, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

47

4 Phase 3, 12 recruiting

FAERS reports

3,369

2,076 serious, 839 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: DIFFERENTIATION SYNDROME Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. Symptoms may include fever, dyspnea, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, lymphadenopathy, bone pain, and hepatic, renal, or multi-organ dysfunction. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution [see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ] . WARNING: DIFFERENTIATION SYNDROME See full prescribing information for complete boxed warning. Patients treated with IDHIFA have experienced symptoms of differentiation syndrome, which can be fatal if not treated. If differentiation syndrome is suspected, initiate corticosteroid therapy and hemodynamic monitoring...

What it is approved for

From the label in effect Jan 16, 2025.

IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ). 1.1 Acute Myeloid Leukemia IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.

Mechanism: Enasidenib is a small molecule inhibitor of the isocitrate dehydrogenase 2 (IDH2) enzyme. Enasidenib targets the mutant IDH2 variants R140Q, R172S, and R172K at approximately 40-fold lower concentrations than the wild-type enzyme in vitro. Inhibition of the mutant IDH2 enzyme by enasidenib led to decreased 2-hydroxyglutarate (2-HG) levels and induced myeloid differentiation in vitro and in vivo in mouse xenograft models of IDH2 mutated AML. In blood samples from patients with AML with mutated IDH2, enasidenib decreased 2-HG levels, reduced blast counts and increased percentages of mature...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 24, 2020 Supplement 4 · Efficacy · priority review OrphanLabelLetter
  • Aug 1, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
  • IDHIFA · ENASIDENIB MESYLATE EQ 100MG BASE · TABLET, ORAL · Prescription
  • IDHIFA · ENASIDENIB MESYLATE EQ 50MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Enasidenib" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death682
  • off label use246
  • fatigue224
  • nausea197
  • hospitalisation186
  • diarrhoea142
  • platelet count decreased133
  • decreased appetite121
  • acute myeloid leukaemia119
  • drug ineffective102
  • asthenia92
  • full blood count decreased81

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201790
2018400
2019424
2020548
2021395
2022317
2023372
2024377
2025276
2026170

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Idhifa (Enasidenib Mesylate)

2024 spending

$185M

Beneficiaries

1,016

5,462 claims

Per beneficiary

$181,791

$1,106.63 per unit

View as table
YearSpending
2020$75,226,515
2021$78,791,111
2022$93,705,063
2023$118,905,343
2024$184,699,247

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.